Accreditation Information

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Contact Hours: 1.0 of which 1.0 is eligible for pharmacology credit


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Needs Statement

Ulcerative Colitis (UC) is a chronic, inflammatory gastrointestinal disease that can have a significant negative impact on the lives of patients. Advances in treatments that are available give patients today a better chance of achieving remission, yet many patients continue to live with symptoms of moderate-to-severe disease. Several gaps in care exist that prevent patients from achieving this treatment goal.

Appropriate treatment for a patient’s disease severity is often not used and evidence-based algorithms are not followed by all gastroenterologists. The introduction of anti-TNF agents revolutionized treatment of UC and now anti-integrin therapies are available, giving patients expanded options for individualized treatment. However, some gastroenterologists are still using traditional step-up treatment strategies in patients with moderate-to-severe UC that delay the initiation of biologic agents in patients who would benefit from their use earlier in therapy. Also, loss of response or primary non-response can occur as well as intolerance to therapy. Gastroenterologists need to be familiar with methods to manage these patients and be aware that new options are in development that could offer alternatives to the agents that are currently used. 

Implementing quality measures and tracking this information can assist gastroenterologists with improving the quality of UC care. Real-world data is becoming a useful tool in assessing overall treatment patterns and applying this data can improve care processes. It can also be useful in evaluating treatment options outside of the controlled clinical trial setting to provide more information about the efficacy, safety, and predictors of response to treatment. Because there are several areas for improvement in UC treatment among gastroenterologists, it is important that clinicians be aware of these deficits and make efforts to examine their own practice to improve the care of their patients.


At the conclusion of this activity, participants will be able to (or better able to):

  1. Identify patients with moderate-to-severe Ulcerative Colitis (UC) who are at high risk for adverse outcomes including surgery and select appropriate treatment for these patients.
  2. Describe reasons for non-response to UC therapy and be able to adjust treatment regimens using evidence-based algorithms and data for various treatment options to help patients attain remission.
  3. Discuss the safety, efficacy, place in therapy, and impact on practice of biologic agents and small molecules that are currently in clinical trials for the treatment of UC.
  4. Analyze real-world data to improve the quality of care provided for UC in clinical practice, scrutinize the safety and efficacy of various treatment options, and review data to find patterns that can provide insights into clinical challenges in UC.

Target Audience

This activity is intended for gastroenterologists, primary care physicians, NP/PAs, nurses and other clinicians who are attending the 2018 ACG Eastern Regional Postgraduate Course, and have an interest in the treatment/management of Ulcerative Colitis (UC).

Faculty Disclosure

Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

Faculty Disclosures

Course Director and Faculty

Francis Farraye, MD, MSc, FACG is a consultant for Braintree, Celgene, Ferring, Janssen, Merck, Pfizer and Takeda, is a stockholder of Innovation Pharmaceuticals Celleutix, and DSMB member for Mesoblast and Protagonist.

Dr. Farraye plans to discuss unlabeled/investigational uses of Azathioprine.


Maria Abreu, MD, FACG is a consultant for Eli Lilly Pharmaceuticals, Janssen, Pfizer, Prometheus Laboratories, Takeda, Theravance Biopharma Us, Inc. and UCB, Inc., is a scientific advisory board member for AbbVie Laboratories, Amgen, Boehringer Ingelheim Pharmaceuticals, Celgene Corporation, MedStar Health, Roche Pharmaceuticals and Shire Pharmaceuticals, is an advisory board member for Allergan and SERES, provides training/consulting for Focus Medical Communications, provides lecturing/teaching for Imedex, Inc., and provides lecturing for CME Outfitters.

Dr. Abreu does not plan to discuss unlabeled/investigational uses of a commercial product.

CNE Course Advisor

Beth-Ann Norton, MS, RN, ANP-BC has no relevant financial relationships to disclose.

Planning Committee

Co-Course Director Bret Lashner, MD, Lead Nurse Planner, Patti-Ann Collins, DNP, MSN, MBA/RN and BU Program Managers Dana Frazier, BBA, CHCP and Joanna Krause, MPH have no relevant financial relationships to disclose.

Independent Reviewer (for ABIM MOC part 2 requirements): Sharmeel Wasan, MD has no relevant financial relationships to disclose.